Literature DB >> 11103773

Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas.

S C Huang1, C A Koch, A O Vortmeyer, S D Pack, U D Lichtenauer, P Mannan, I A Lubensky, G P Chrousos, R F Gagel, K Pacak, Z Zhuang.   

Abstract

Inherited mutations of the RET proto-oncogene are tumorigenic in patients with multiple endocrine neoplasia type 2 (MEN 2). However, it is not understood why only few of the affected cells in the target organs develop into tumors. Genetic analysis of nine pheochromocytomas from five unrelated patients with MEN 2 showed either duplication of the mutant RET allele in trisomy 10 or loss of the wild-type RET allele. Our results suggest a "second hit" causing a dominant effect of the mutant RET allele, through either duplication of the mutant allele or loss of the wild-type allele, as a possible mechanism for pheochromocytoma tumorigenesis in patients with MEN 2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103773

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Chromosome 2 (2p16) abnormalities in Carney complex tumours.

Authors:  L Matyakhina; S Pack; L S Kirschner; E Pak; P Mannan; J Jaikumar; S E Taymans; F Sandrini; J A Carney; C A Stratakis
Journal:  J Med Genet       Date:  2003-04       Impact factor: 6.318

Review 2.  Molecular pathogenesis of MEN2-associated tumors.

Authors:  Christian A Koch
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  High polymorphism in the trisomic portion of a gastric cancer cell line.

Authors:  Blake A Jacobson; James M Fink; Bryan A Whitson; Lance J Ferrin
Journal:  J Gastroenterol       Date:  2007-03-30       Impact factor: 7.527

4.  Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome.

Authors:  M Poturnajova; V Altanerova; L Kostalova; J Breza; C Altaner
Journal:  J Mol Med (Berl)       Date:  2004-12-09       Impact factor: 4.599

5.  Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele.

Authors:  Carrie Graveel; Yanli Su; Julie Koeman; Ling-Mei Wang; Lino Tessarollo; Michele Fiscella; Carmen Birchmeier; Pamela Swiatek; Roderick Bronson; George Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-22       Impact factor: 11.205

6.  High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma.

Authors:  Lei Ye; Libero Santarpia; Gilbert J Cote; Adel K El-Naggar; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2008-09-02       Impact factor: 5.958

Review 7.  Long-term follow up of a "sporadic" unilateral pheochromocytoma revealing multiple endocrine neoplasia MEN2A-2 in an elderly woman.

Authors:  Andreas Weinhäusel; Annemarie Behmel; Bruce A J Ponder; Oskar A Haas; Bruno Niederle; Alois Gessl; Heinrich Vierhapper; Roswitha Pfragner
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

8.  Pheochromocytoma in von hippel-lindau disease: distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2.

Authors:  Christian A Koch; David Mauro; McClellan M Walther; W Marston Linehan; Alexander O Vortmeyer; Ronald Jaffe; Karel Pacak; George P Chrousos; Zhengping Zhuang; Irina A Lubensky
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  Black swans - neuroendocrine tumors of rare locations.

Authors:  Christian A Koch; S Petersenn
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

10.  ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.

Authors:  Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.